Welcome to our dedicated page for Corbus Pharmaceu SEC filings (Ticker: CRBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corbus Pharmaceuticals Holdings, Inc. (CRBP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-assisted context for key documents. Corbus is a clinical-stage oncology and obesity company, and its filings reflect the financial, clinical, and governance developments associated with advancing drug candidates such as CRB-701, CRB-601, and CRB-913.
Investors can review Form 8‑K current reports in which Corbus discloses material events, including quarterly financial results, preliminary cash and investment balances, Fast Track designations for CRB-701, and entry into material definitive agreements such as underwriting agreements for public offerings of common stock and pre-funded warrants. Certain 8‑K filings also describe board-level changes, such as the planned retirement of a director, and clarify that such departures are not due to disagreements over company operations or policies.
Quarterly and annual financial information referenced in 8‑K exhibits is complemented by the company’s full 10‑Q and 10‑K reports, which are accessible through EDGAR and summarized by Stock Titan’s AI tools. These reports typically include detailed discussions of research and development spending, net losses associated with clinical-stage operations, and liquidity and capital resources, including the impact of public offerings and at-the-market sales programs.
For users interested in insider and governance activity, Form 4 and related ownership filings, when available, can be used to track changes in beneficial ownership by directors and officers. Stock Titan’s platform surfaces new filings in near real time and applies AI-powered summaries to highlight the sections that matter most, such as clinical program updates, risk factor changes, and financing terms. This allows readers to navigate lengthy SEC documents more efficiently while still being able to drill down into the original filings for full detail.
Corbus Pharmaceuticals (CRBP) launched a preliminary prospectus supplement for a primary offering of common stock and, at investors’ election, pre‑funded warrants, with the underwriters granted a 30‑day option to purchase additional shares. The pre‑funded warrants are immediately exercisable for one share at an exercise price of $0.0001 per share and include a 9.99% Beneficial Ownership Limitation (electable up to 19.99% with notice).
The company plans to use net proceeds to fund clinical development across its oncology and obesity programs and for working capital and general corporate purposes. As context, the stock last closed at $16.86 on October 29, 2025, and Corbus preliminarily estimates cash, cash equivalents, and investments of approximately $104.0 million as of September 30, 2025. Since June 30, 2025, it sold 505,217 shares via its at‑the‑market program for $6.7 million. Shares outstanding were 12,254,069 as of June 30, 2025, after giving effect to those ATM sales.
Corbus Pharmaceuticals (CRBP) CEO and director Yuval Cohen reported insider transactions on a Form 4. On 10/24/2025 and 10/27/2025, he exercised stock options at $4.26 per share and sold the same number of common shares under a Rule 10b5-1 trading plan adopted on March 14, 2025.
He exercised 18,660 options on 10/24 and sold 18,660 shares at a weighted average price of $17.01 (range $16.79–$17.38). He exercised 8,973 options on 10/27 and sold 8,973 shares at a weighted average price of $17.14 (range $17.00–$17.31).
Following these transactions, he beneficially owned 138,187 shares, which includes 123,561 unvested RSUs subject to vesting schedules. Remaining derivative holdings include 22,106 stock options at an exercise price of $4.26 expiring on 02/13/2033.
Corbus Pharmaceuticals (CRBP) Form 4: On 10/24/2025, the company’s Chief Financial Officer exercised stock options for 12,981 shares at $4.26 per share (Code M) and sold 12,981 common shares at a weighted average price of $17.02 (Code S) pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025.
Following these transactions, the officer beneficially owns 73,313 shares; this amount includes 57,632 unvested RSUs subject to each grant’s vesting schedule. The reported sale occurred in multiple trades ranging from $16.79 to $17.38. The option award was granted under the 2014 Equity Compensation Plan, with 25% vesting on February 13, 2024 and the remainder vesting monthly over 36 months commencing on March 13, 2024.
Corbus Pharmaceuticals (CRBP) director Anne Altmeyer reported an option exercise and same‑day sale. On 10/20/2025, she exercised 1,060 stock options at $4.8 per share (code M) and sold 1,060 common shares at $20.5 (code S). After these transactions, she beneficially owned 6,191 common shares directly.
The filing notes a Rule 10b5‑1 trading plan adopted on 11/14/2024 governed the sale. It also states her holdings include 4,800 unvested RSUs granted on 05/30/2025 that vest 100% on the one‑year anniversary of grant. Following the exercise, 4,247 options remain outstanding, fully vested, at a $4.8 exercise price expiring on 09/26/2032.
Corbus Pharmaceuticals Holdings, Inc. reported that the U.S. Food and Drug Administration has granted Fast Track designation to its drug candidate CRB-701 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in patients previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy. The company disclosed this designation through a current report and attached the related press release as an exhibit.